'Younger people are taking steps to prevent lifestyle diseases.'
'It is fascinating to partner with consumers on the journey of self-discovery and to help shape people's preferences -- that is what I find most exciting,' Nandini Piramal tells Abhineet Kumar and Aneesh Phadnis.
Once the bankruptcy provisions are notified, these proprietary firms will benefit, as Insolvency and Bankruptcy Board plans to consider them as individuals
The commercial vehicle business is one of the mainstays for the Tata group, highlighting the importance of Girish Wagh's appointment.
Invests $1.1 billion in 6 months, against $3.7 billion in 20 years
Deposit amount can equal investor's stake, won't impact his holding as it is a loan
'And the top 10 per cent will grow because they have to serve the market.'
The Pradhan Mantri Jan Aushadhi Yojana or PMJAY has not been a runaway success by any yardstick. Not all stores are running, and many are poorly stocked.
According to BJP strategists, PMJAY and the PM Ujjwala Yojana will form the nucleus of the Modi government's re-election campaign.
NPPA's decision would also benefit domestic stent makers.
Tata Communications has elected the private equity (PE) veteran as a successor to Subodh Bhargava.
He's betting big on small stores to help him reach 10 million households by FY21, report Abhineet Kumar and Raghavendra Kamath.
They play a key role in managing rescue and liquidation processes envisaged under the Code
The regulator is now probing 24 hospitals, including Max Hospital in New Delhi and Lilavati in Mumbai, for allegedly overcharging patients for stents
The National Pharmaceutical Pricing Authority has decided to have one price for basic utility condoms and the other for pleasure condoms.
MicroPort entered the market on Feb 15 and its stent was used in a Mumbai hospital.
The Essar Oil, Rosneft deal also helped Arpwood Capital, boutique investment bank, co-founded by Rajeev Gupta and Raj Kataria, to grab the second spot in the mergers and acquisitions league table.
Sun Pharmaceutical, which is growing its dermatology and ophthalmic specialty business in the US will spend $460 million on R&D.
Aneesh Phadnis and Veena Mani find out what the manufacturers and the hospitals have to say.
Netmed plans to procure from drug manufacturers and sell to pharmacies it has tie-ups with, and to spread its network to all tier-II and tier-III cities.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances